Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostrate cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Prostatic Neoplasms
  • Radiotherapy, Conformal

abstract

  • Neoadjuvant and concomitant EV with high-dose 3D-CRT is well tolerated in patients with unfavorable-risk prostate cancer. Although the incidence of modest (grade 2) late GI and GU toxicities seem to be increased compared with 3D-CRT alone or in combination with androgen ablation therapy, no severe toxicities were encountered with this regimen.

publication date

  • May 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10784635

Additional Document Info

start page

  • 1936

end page

  • 41

volume

  • 18

number

  • 9